Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5927
Title: CYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophrenia
Authors: Balıbey, Hakan
Başoğlu, Cengiz
Lundgren, Stefan
Babaoğlu, Melih Ö.
Yaşar, Ümit
Herken, Hasan
Rane, Anders
Bozkurt, Atilla
Çetin, Mesut
Keywords: Clozapine
CYP1A2
Schizophrenia
Smoking
clozapine
cytochrome P450 1A2
cytochrome P450 1A2 1F
unclassified drug
adult
article
biochemistry
Brief Psychiatric Rating Scale
cigarette smoking
drug dose increase
drug megadose
female
follow up
gene frequency
genetic polymorphism
genotype
human
major clinical study
male
psychologic assessment
psychologic test
psychosis
retrospective study
Scale for the Assessment of Negative Symptom
Scale for the Assessment of Positive Symptom
schizophrenia
single nucleotide polymorphism
treatment duration
treatment response
wild type
Abstract: Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or occurrence of side effects of antipsychotic drugs. Aim: We studied the association of response to clozapine treatment in schizophrenic patients in relation to polymorphisms in the CYP1A2 gene. Methods: The degree of psychosis of the patients (n=55) was assessed using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS) and routine biochemistry. The patients were monitored for 18 weeks and the scales were applied before starting the treatment and at the end of the follow up period. Clozapine was used at doses of 200 to 600 mg/day. A positive response was defined as a 20% decrease in pre-and posttreatment scores of one of the BPRS, SANS, or SAPS scores. In addition, 45 patients, who were already on clozapine treatment, were assessed retrospectively. Results: As assessed at the 18th week after start of therapy, lack of response to clozapine treatment was 2.4 fold higher in the patients carrying the CYP1A2*1F*1F genotype (p=0.02) compared to patients carrying at least one wild type allele (i.e. *1/*1 or *1/*1F). Smoking decreased the response rate by about 15% (p=0.014). Conclusion: The results of our study suggest that the CYP1A2*1F/*1F genotype may be a risk factor for lack of response to clozapine treatment in psychotic patients, especially in cigarette smokers.
URI: https://hdl.handle.net/11499/5927
https://doi.org/10.5455/bcp.20110622071701
ISSN: 1017-7833
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
f78c31f0-aa7a-4003-acf1-d39625191b7d.pdf277.96 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

23
checked on Nov 23, 2024

WEB OF SCIENCETM
Citations

20
checked on Nov 22, 2024

Page view(s)

52
checked on Aug 24, 2024

Download(s)

16
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.